Shunji Haruta
Direttore Tecnico/Scientifico/R&S presso SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
Posizioni attive di Shunji Haruta
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. | Direttore Tecnico/Scientifico/R&S | 01/01/2011 | - |
| SATSUMA PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 08/06/2023 | - |
Storia della carriera di Shunji Haruta
Statistiche
Distribuzione geografica
| Giappone | 2 |
| Stati Uniti | 2 |
Posizioni
| Chief Tech/Sci/R&D Officer | 1 |
| Director/Board Member | 1 |
Settori
| Commercial Services | 2 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. | Commercial Services |
| Aziende private | 1 |
|---|---|
Satsuma Pharmaceuticals, Inc.
 Satsuma Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraines. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in Durham, NC. | Health Technology |
- Borsa valori
- Insiders
- Shunji Haruta
- Esperienza
